Compare · ASND vs NVO
ASND vs NVO
Side-by-side comparison of Ascendis Pharma A/S (ASND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $206.96B, about 13.2x ASND ($15.70B).
- Over the past year, ASND is up 33.3% and NVO is down 17.0% - ASND leads by 50.3 points.
- ASND has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Ascendis Pharma A/S
- Novo Nordisk A/S
- Price
- $253.80-0.44%
- $46.73+1.19%
- Market cap
- $15.70B
- $206.96B
- 1M return
- +0.47%
- -3.03%
- 1Y return
- +33.31%
- -17.03%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 25
Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ASND
- BMO Capital Markets initiated coverage on Ascendis Pharma with a new price target
- Director Bienaime Jean Jacques bought $492,654 worth of Ordinary Shares (2,000 units at $246.33), increasing direct ownership by 222% to 2,900 units (SEC Form 4)
- Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
- Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis Pharma Reports Second Quarter 2026 Financial Results
- SEC Form 6-K filed by Ascendis Pharma A/S
- Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
- SEC Form 6-K filed by Ascendis Pharma A/S
Latest NVO
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S